Abstract 928P
Background
The prediction of early response in locally advanced nasopharyngeal carcinoma (LA-NPC) after concurrent chemoradiotherapy (CCRT) is indeed important for determining the need for timely consolidation therapy. Radiomics has helped medical imaging expand from diagnostic to a personalized clinical decision aid, while most traditional radiomics primarily focus on mono-sequence. Recently, multi-MR sequences model has shown better outcomes in the management of many cancers. However, the validation of a radiomic analysis of multi-MR sequences based on machine learning for this purpose is currently lacking for patients with LA-NPC after CCRT.
Methods
This study comprised 104 patients with LA-NPC, of which 70% were allocated for training and the remaining 30% were used for internal validation. We extracted radiomics features corresponding to each mono-sequences (T1, T1C, T2, DWI, and ADC), and then applied LASSO for feature selection and constructed the risk model using machine learning algorithms including SVM, Random Forest, ExtraTrees, XGBoost and LightGBM. Performance comparisons were made between mono-sequences and then feature fusion was performed to construct a multi-MR sequences model. Clinical features were numerically mapped and analyzed using machine learning algorithms similar to those in the Radiomics Model. Finally, we created a combined model that integrated the radiomics and clinical models to enhance clinical relevance, whose diagnostic effectiveness was evaluated using receiver operator characteristic (ROC) curves in the test cohort.
Results
In the training cohort, while the Clinic model achieved an Area Under the Curve (AUC) of 0.892 and the Fusion model reached 0.972, the Combined model excelled with an AUC of 0.990. Similarly, in the test cohort, the Combined model outperformed both the Clinic (AUC: 0.852) and Fusion models (AUC: 0.886), achieving an AUC of 0.900.
Conclusions
As a result, a combined model, which merges clinical and multi-MR sequences radiomics model, showed good performance for predicting early response of LA-NPC after CCRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program and Jiangsu Province People's Hospital Clinical Capability Enhancement Project.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03